Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Vanessa Beard-Ely

Physician Assistant Murray, UT Physician Assistant

NPI 1730140484 CMS profile 11092728

5171 S Cottonwood St, Ste 810, Murray, UT 84107

Open in the dashboard

General payments

$79,830

893 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vanessa Beard-Ely of Murray, UT is reported in the CMS Open Payments database as having received $79,830 across 893 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,375 22
2024 General $14,646 169
2023 General $16,637 280
2022 General $10,733 217
2021 General $36,439 205

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vanessa Beard-Ely
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Vanessa Beard-Ely were reported at $1,375. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Vanessa Beard-Ely Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $36,439 $132 $37–$438 $132
2022 $10,733 $155 $48–$522 $149
2023 $16,637 $167 $52–$557 $160
2024 $14,646 $178 $55–$600 $164
2025 $1,375 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biohaven Pharmaceuticals, Inc. $34,867 88 payments
  2. AbbVie, Inc. $22,838 179 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $8,620 67 payments
  4. Pfizer Inc. $4,336 92 payments
  5. Medtronic, Inc. $2,183 51 payments
  6. Teva Pharmaceuticals USA, Inc. $1,557 122 payments
  7. SK Life Science, Inc. $1,274 109 payments
  8. Boston Scientific Corporation $1,144 7 payments
  9. Neurocrine Biosciences, Inc. $370 15 payments
  10. ACADIA Pharmaceuticals Inc $321 34 payments
  11. Other $2,321 129 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $64,355 70 payments
  2. Food and Beverage $11,606 808 payments
  3. Consulting Fee $1,920 1 payment
  4. Travel and Lodging $1,807 9 payments
  5. Education $142 5 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $43,487 155 payments
  2. UBRELVY $20,513 107 payments
  3. QULIPTA $10,639 103 payments
  4. PERCEPT PC BRAINSENSE $1,736 38 payments
  5. AJOVY $746 61 payments
  6. Austedo XR $592 44 payments
  7. NURTEC ODT Pain $572 84 payments
  8. ZAVZPRET $401 62 payments
  9. ZEPOSIA $399 21 payments
  10. SenSight $354 10 payments
  11. Other $3,400 210 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

4,570

Median for Physician Assistant: 241

Drug cost

$1,490,551

Median for Physician Assistant: $4,110

Branded share of claims

36.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 52 $279,599
Copaxone Glatiramer Acetate Brand 15 $146,054
Nurtec Odt Rimegepant Sulfate Brand 95 $107,450
Botox Onabotulinumtoxina Brand 81 $103,046
Emgality Pen Galcanezumab-Gnlm Brand 110 $94,192
Xcopri Cenobamate Brand 75 $88,237
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 15 $83,172
Ajovy Autoinjector Fremanezumab-Vfrm Brand 91 $80,897
Aimovig Autoinjector Erenumab-Aooe Brand 100 $79,002
Aptiom Eslicarbazepine Acetate Brand 34 $74,107

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$36,162

Of which drugs: $5,233

Medicare patients

238

Average age 72

Services billed

2,115

135 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 54%
Depression 42%
Ischemic heart disease 26%
Diabetes 25%
Alzheimer's or dementia 23%
Chronic kidney disease 21%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$6,526 55 —
QULIPTA
$1,595 12 —
Austedo XR
$396 — —
ZEPOSIA
$145 — —
NURTEC ODT
$116 95 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

893 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record